Verona seeks anti-cough partner following strong showing in the clinic
This article was originally published in Scrip
Executive Summary
Verona Pharma will wait for ongoing discussions with potential investors or partners to bear fruit before continuing clinical development of VRP700, its promising anti-cough candidate, CEO Michael Walker (founder and former chairman of Canadian firm Cardiome Pharma) told Scrip.